Thoracic radiotherapy may enhance the survival of patients with low-risk advanced lung adenocarcinoma based on protein biomarkers

Chunliu Meng; Fang Wang; Juan Wang; Jia Tian; Xue Li; Haijun Lu; Lujun Zhao; Ping Wang

doi:10.1002/pro6.70053

Precision Radiation Oncology ›› 2026, Vol. 10 ›› Issue (1) :27 -38. DOI: 10.1002/pro6.70053

ORIGINAL ARTICLE

Thoracic radiotherapy may enhance the survival of patients with low-risk advanced lung adenocarcinoma based on protein biomarkers

Author information +

History +

PDF (4025KB)

Abstract

Objectives: Several clinical trials have demonstrated promising outcomes with thoracic radiotherapy (TRT) in patients with advanced lung adenocarcinoma (LUAD). However, a subset of patients derives no significant survival benefit from TRT. This study aimed to develop a risk model integrating biomarkers and clinical factors to identify patients most likely to benefit from TRT.

Methods: Prognostic proteins associated with LUAD survival were identified using data from The Cancer Proteome Atlas. Immunohistochemical analysis was performed to evaluate protein expression in patients with advanced LUAD treated at our institution between 2015 and 2019. Univariate and multivariate Cox regression analyses were conducted to determine clinical factors influencing prognosis. A risk model combining biomarkers and clinical variables was constructed to generate individualized risk scores.

Results: Four proteins, PAI-1, KU80, FOXO3A_pS318S321, and CKIT, were selected for further analysis. A total of 272 patients were divided into training (n = 181) and validation (n = 91) cohorts. Six prognostic factors including N-stage, presence of sensitive mutations, brain metastasis, adrenal metastasis, leukocyte count, and expression levels of PAI-1 and KU80 were incorporated into the risk model. Patients were stratified into low- and high-risk groups based on calculated risk scores. TRT significantly improved median survival time (69.0 vs. 39.3 months, p = 0.003) and overall survival (67.4 vs. 33.0 months, p = 0.035) in low-risk patients, but not in high-risk patients (median survival time: 19.8 vs. 18.2 months, p = 0.186; overall survival: 19.4 vs. 19.9 months, p = 0.607) for two cohorts.

Conclusion: Multiple biomarkers and clinical variables are associated with prognosis in LUAD. The risk model developed herein indicates that TRT confers a survival benefit exclusively in patients classified as low risk.

Keywords

biomarkers / lung adenocarcinoma / risk model / thoracic radiotherapy

Cite this article

Download citation ▾

Chunliu Meng, Fang Wang, Juan Wang, Jia Tian, Xue Li, Haijun Lu, Lujun Zhao, Ping Wang. Thoracic radiotherapy may enhance the survival of patients with low-risk advanced lung adenocarcinoma based on protein biomarkers. Precision Radiation Oncology, 2026, 10 (1) : 27-38 DOI:10.1002/pro6.70053

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2]	Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185): 2051-2058.

[3]	Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019; 37(18): 1558-1565.

[4]	Xu Q, Zhou F, Liu H, et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018; 13(9): 1383-1392.

[5]	Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018; 4(1):e173501.

[6]	Farooqi A, Ludmir EB, Mitchell KG, et al. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiother Oncol. 2021; 163: 114-118.

[7]	Chan OSH, Lam KC, Li JYC, et al. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer. 2020; 142: 41-46.

[8]	Wang XS, Bai YF, Verma V, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023; 115(6): 742-748.

[9]	Jethwa KR, Jang S, Mullikin TC, et al. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiother Oncol. 2020; 146: 29-36.

[10]	Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017; 12(7): 1109-1121.

[11]

Sun H, Li M, Huang W, et al. Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial. J Clin Oncol. 2025; 43(4): 412-421.

[12]	Iyengar P, Hu C, Gomez DR, et al. NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2024; 42(16_suppl): 8506.

[13]	Sun Z, Wen J, Cui W, Yu M, Li Y, Meng X. Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy. Crit Rev Oncol Hematol. 2025; 214:104853.

[14]	Wang M, Li S, Li R, Ning F, Tian L. Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2024; 25(12): 1605-1614.

[15]	Yang Y, Liu T, Mi S, et al. Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review. Transl Lung Cancer Res. 2025; 14(2): 591-606.

[16]	Li X, Wang Y, Wang J, et al. Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer. Int J Cancer. 2018; 143(1): 212-224.

[17]	Shen R, Liu D, Wang X, et al. DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling. Front Cell Dev Biol. 2022; 9:828657.

[18]	Meng C, Wei J, Tian J, et al. Estimating survival and clinical outcome in advanced non-small cell lung cancer with bone-only metastasis using molecular markers. J Bone Oncol. 2021; 31:100394.

[19]	Qi J, Zhang J, Ge X, et al. The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients. Front Oncol. 2021; 11:713014.

[20]

Gu W, Hu M, Xu L, et al. The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status. Front Med (Lausanne). 2021; 8:728575. Published 2021 Nov 5.

[21]	Dall'Olio FG, Abbati F, Facchinetti F, et al. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2020; 12:1758835920952994. Published 2020 Oct 31.

[22]	Bharadwaj AG, Holloway RW, Miller VA, Waisman DM. Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. Cancers (Basel). 2021; 13(8): 1838.

[23]	Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014; 86(1): 78-84.

[24]	Morrow GB, Mutch NJ. Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Semin Thromb Hemost. 2023; 49(3): 305-313.

[25]	Tokumo K, Masuda T, Nakashima T, et al. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition. Cancers (Basel). 2023; 15(4): 1092.

[26]	Li S, Wei X, He J, Tian X, Yuan S, Sun L. Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother. 2018; 105: 83-94.

[27]	Zhang YP, Guo ZQ, Cai XT, et al. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell. 2025; 43(5): 856-874.e9.

[28]	Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020; 5(1): 60.

[29]	Shang B, Jia Y, Chen G, Wang Z. Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells. Respir Res. 2017; 18(1): 56.

[30]	Ma Q, Li P, Xu M, et al. Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. J Exp Clin Cancer Res. 2012; 31(1): 99.